- Home
- OPFI vs LFCR Comparison
OPFI vs LFCR Comparison
Compare OPFI & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.97
Company Overview
Basic Information| Metric | OPFI | LFCR |
|---|---|---|
| Founded | 2009 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 296.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPFI | LFCR |
|---|---|---|
| Price | $10.23 | $7.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 541.4K | 176.2K |
| Earning Date | 10-29-2025 | 01-02-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $335,423,000.00 | $128,867,000.00 |
| Revenue This Year | $120.32 | $2.80 |
| Revenue Next Year | $10.85 | $11.51 |
| P/E Ratio | $76.54 | ★ N/A |
| Revenue Growth | ★ 28.69 | 0.47 |
| 52 Week Low | $6.81 | $4.76 |
| 52 Week High | $17.73 | $8.85 |
Technical Indicators
Market Signals| Indicator | OPFI | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 51.25 |
| Support Level | $10.09 | $7.45 |
| Resistance Level | $10.70 | $8.36 |
| Average True Range (ATR) | 0.43 | 0.42 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 12.95 | 38.80 |
Price Performance
Historical Comparison OPFI
LFCR
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.